^
    20d
    C2321001: A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov)
    P1, N=433, Recruiting, Pfizer | Trial completion date: Mar 2026 --> Mar 2029 | Trial primary completion date: Mar 2026 --> May 2028
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • itraconazole • mevrometostat (PF-06821497)
    2ms
    This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. (clinicaltrials.gov)
    P3, N=1000, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Xtandi (enzalutamide) • mevrometostat (PF-06821497)
    6ms
    This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. (clinicaltrials.gov)
    P3, N=1000, Not yet recruiting, Pfizer
    New P3 trial
    |
    Xtandi (enzalutamide) • mevrometostat (PF-06821497)
    7ms
    A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov)
    P1, N=0, Withdrawn, Pfizer | N=16 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    mevrometostat (PF-06821497)
    8ms
    Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov)
    P1, N=343, Recruiting, Pfizer | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • mevrometostat (PF-06821497)
    11ms
    A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Pfizer | Trial completion date: Apr 2025 --> Sep 2025 | Initiation date: Dec 2024 --> Apr 2025 | Trial primary completion date: Apr 2025 --> Sep 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    mevrometostat (PF-06821497)
    11ms
    A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of PF-06821497 (Mevrometostat) in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (MEVPRO-2) (ChiCTR2400093511)
    P3, N=900, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P3 trial
    |
    Xtandi (enzalutamide) • mevrometostat (PF-06821497)
    12ms
    A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body. (clinicaltrials.gov)
    P1, N=6, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    mevrometostat (PF-06821497)
    1year
    A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body. (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    mevrometostat (PF-06821497)
    1year
    A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Pfizer
    New P1 trial
    |
    mevrometostat (PF-06821497)
    1year
    A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. (clinicaltrials.gov)
    P3, N=900, Recruiting, Pfizer
    New P3 trial • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • mevrometostat (PF-06821497)
    1year
    A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body. (clinicaltrials.gov)
    P1, N=6, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    mevrometostat (PF-06821497)